Southern Research Institute to Present at the 2007 American Association For Cancer Research Annual Meeting

BIRMINGHAM, Ala., April 3 /PRNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery and drug development today announced that its scientists will be delivering one oral presentation and 10 poster presentations at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif.

Anshu Mittal Roy of Southern Research will be presenting new data on the different factors that contribute to tumor growth. The discussion titled "VEGF Overexpression Increases Stromal Content in Both Primary Tumor and Metastatic Lesions" will be presented on Tuesday, April 17, from 11:25 a.m. - 11:40 a.m. in Room 404 A-B, Los Angeles Convention Center.

Scientists from Southern Research will also present preclinical data in posters at the Exhibit Hall:

  Sunday, April 15
   -- Jose T. Thaiparambil will be presenting poster (#644) "Sulindac
      Sulfide Selectively Inhibits cGMP PDE from Human HT-29 Colon Tumor
      Cells" from 8:00 a.m. -12:00 p.m.

   -- Patricia E. Noker will be presenting poster (#1545) "Toxicity and
      Pharmacokinetics of 1-Methyl-D-Tryptophan in Rats and Dogs" from 1:00
      p.m. - 5:00 p.m.

  Monday, April 16
   -- Rongbao Li will be presenting poster (#3165) "Structural Basis for
      PYK2 Adhesion Targeting" from 1:00 p.m. - 5:00 p.m.

   -- Adam B. Keeton will be presenting poster (#2282) "Reversal of MRP-1
      Mediated Multi-Drug Resistance by Sulinda Sulfide and Indomethacin"
      from 8:00 a.m. - 12:00 p.m.

  Tuesday, April 17
   -- Bo Xu will be presenting poster (#3895) "Regulation of ATM
      Phosphorylation in the Absence of DNA Damage" from 8:00 a.m. - 12:00
      p.m.

   -- Mickael J. Cariveau will be presenting poster (#3893) "Interfering
      with NBS1-ATM Interaction to Inhibit the DNA Damage Response and
      Sensitize Tumor Cells to Radiation" from 8:00 a.m. - 12:00 p.m.

   -- Jaideep V. Thottassery will be presenting poster (#4375) "Cks1
      Regulates Cdk1 Expression: A novel Role during Mitotic Entry in Breast
      Cancer Cells" from 1:00 p.m. - 5:00 p.m.

   -- Yonghe Li will be presenting poster (#4385) "Opposing Roles of Dkk1 in
      LRP6 Stabilization and Wnt Signaling: Implication for Wnt Ligand-
      induced LRP6 Down-regulation" from 1:00 p.m. - 5:00 p.m.

   -- Zhican Qu will be presenting poster (#8935) "Screening for Specific
      Anti-angiogenic Agents" from 1:00 p.m. - 5:00 p.m.

  Wednesday, April 18
   -- Bo Xu will be presenting poster (#5055) "Clofarabine Acts
      Synergistically with Ionizing Radiation In Vitro and In Vivo by
      Inhibiting the Repair of DNA Damage" from 8:00 a.m. - 12:00 p.m.

To date, Southern Research has discovered six of the FDA-approved anti- cancer drugs and four additional drugs that are currently in clinical trials. Further, Southern Research has evaluated almost 70% of all other FDA-approved cancer drugs on the market. Seventy-five percent of all FDA approved HIV drugs have also been evaluated at Southern Research during development.

ABOUT SOUTHERN RESEARCH

Southern Research is a not-for-profit organization that conducts scientific research at facilities in Alabama, Florida, Maryland and North Carolina. Southern Research provides contract research in the fields of preclinical drug discovery and development, advanced engineering, environmental and energy-related research. For more information, see http://www.southernresearch.org/.

  Media Contacts:

  Rhonda Jung                      Risa Burgess
  205-581-2317                     781-684-0770
  Southern Research Institute      Schwartz Communications, Inc.
  Jung@SouthernResearch.org        Southern@schwartz-pr.com